ClinicalTrials.gg
RecruitingNCT07428356HALTUpdated Oct 8, 2026

Histotripsy for Ablation of Liver Tumours in Asia

An interventional study of Histotripsy using HistoSonics Edison™ System in Liver Malignant Tumors, sponsored by National Cancer Centre, Singapore. Recruiting at 3 sites in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by National Cancer Centre, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 8, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore — 4 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · National Cancer Centre, Singapore.

Planned enrollment
5th of 11
40 · median 40
Started
2025
the only one that year
No phase
2 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 17th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

4 of the 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Hepatocellular by National Cancer Centre, Singapore, or all of them as a file.
02

Study summary

The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.

Read the detailed description

This will be a single-arm, multi-centre, prospective pilot study enrolling patients with:

A) Liver limited malignancies (primary or secondary) not eligible for/declined resection or other locoregional treatment modalities.

B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received > 3 months of systemic therapy).

Patients will undergo baseline imaging and laboratory investigations, followed by histotripsy treatment under general anaesthesia. Post-procedure assessments will be performed at predefined intervals for clinical, radiologic, and biomarker evaluation.

03

Conditions studied

  • Liver Malignant Tumors

Keywords

  • Histotripsy
  • Ablation of Liver Tumours
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥21 years at the time of consent.
  2. Histologically/ confirmed cancers (imaging diagnosis as per AASLD allowed for HCC):

    A) Liver limited (primary or secondary) not eligible for/declined resection or other locoregional treatment modalities.

    B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received > 3 months of systemic therapy).

  3. Characteristics of hepatic lesions intended for treatment:

    • Up to 3 hepatic lesions.
    • Tumour ≤ 3 cm in longest diameter.
    • Lesion(s) must be visible and targetable by ultrasound.
  4. Performance Status 0-1.
  5. class A or B7 liver function for patients with underlying cirrhosis.
  6. Adequate hematologic and organ function within 14 days prior to treatment:

    • ≥ 9.0 g/dL
    • ≥ 75,000/mm³
    • ≤ 1.5 ×
    • Estimated (by Cockroft-Gault or Modification of Diet in Renal Disease () or measured ≥ 50ml/min.
    • Total ≤ 1.5 × upper limit normal or direct bilirubin ≤ ULN for participants with total bilirubin > 1.5 × ULN (participants with known history of elevated indirect bilirubin level suggestive of extrahepatic source of elevation e.g. Gilbert's disease may be recruited with bilirubin levels ≤ 3 × ULN)
    • and ALT ≤ 5 × ULN
  7. Ability to undergo general anaesthesia, as confirmed by pre-anaesthetic assessment.
  8. ≥ 3 months in the opinion of the investigator.
  9. Willing and able to comply with study visits and procedures.
  10. Written obtained prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Extrahepatic disease progression requiring immediate systemic intervention, including new or malignant ascites.
  2. Vascular invasion, defined as gross involvement or encasement of major portal vein or hepatic vein branches.
  3. Tumours located adjacent (\<5 mm) to hollow viscera (e.g., stomach, colon) where histotripsy poses perforation risk.
  4. Lesions poorly visualized on ultrasound or not targetable due to overlying ribs or gas.
  5. Severe or uncontrolled comorbidities including:

    • Uncontrolled hypertension or cardiovascular disease
    • Active infection (requiring systemic therapy)
    • Severe or hypoxia
  6. to general anaesthesia or surgery.
  7. Pregnancy or breastfeeding. Women of must have a negative pregnancy test within 7 days prior to treatment.
  8. Participation in another interventional trial within 4 weeks prior to enrollment, or concurrent participation in a therapeutic study.
  9. Any condition that, in the investigator's judgment, may compromise the patient's safety or interfere with protocol adherence.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Histotripsy Group

    Histotripsy for Ablation of Liver Tumours.

    Device: Histotripsy using HistoSonics Edison™ System

Interventions

  • DeviceHistotripsy using HistoSonics Edison™ System

    The histotripsy procedure will be performed using the HistoSonics Edison™ System, an image-guided, non-invasive focused ultrasound platform specifically designed for mechanical tissue fractionation. Key steps include general anaesthesia and positioning, pre-treatment planning and imaging, and histotripsy ablation procedure.

06

What researchers measure

Primary outcomes

  1. 6-month local control rate.

    Proportion of patients with absence of local tumour progression at the treated site as per RECIST version 1.1 criteria.

    Time frame: 6 months post-procedure.

  2. Major complication rate.

    Incidence of treatment-related adverse events (AEs) of grade ≥3 (CTCAE v5.0) within 30 days post-procedure.

    Time frame: 30 days post-procedure.

Secondary outcomes

  1. 36-hour technical success rate.

    Proportion of patients with tumour treated volume ≥ targeted volume with complete tumour coverage, evaluated using contrast-enhanced MRI/CT.

    Time frame: 36 hours post-procedure.

  2. 30-day technique efficacy rate.

    Proportion of patients with absence of nodular or mass-like enhancement within or along the treatment volume

    Time frame: 30 days post-procedure.

Other outcomes

  1. Longitudinal Response Evaluation and patterns of progression.

    Percentage change of tumour sizes from baseline to each of the timepoints specified in the protocol. Pattern of progression will be tabulation (frequency + percentages) of the pattern of progression

    Time frame: 3 months, 6 months, 1 year and 2 years post-procedure.

  2. Changes in quality-of-life post-histotripsy, based on EORTC QLQ-C30 scores.

    Change of scores based on EORTC QLQ-C30 for liver malignancies from baseline to each of the timepoints specified in the protocol

    Time frame: 30 days, 3 months, 6 months, 1 year and 2 years post-procedure.

  3. Changes in quality-of-life post-histotripsy, based on EORTC QLQ-HCC18 scores.

    Change of scores based on EORTC QLQ-HCC18 for liver malignancies from baseline to each of the timepoints specified in the protocol

    Time frame: 30 days, 3 months, 6 months, 1 year and 2 years post-procedure.

  4. Immune Response Analysis based on Information from Immune Biomarkers.

    Evaluation of changes in circulating immune biomarkers post-histotripsy.

    Time frame: 36 hours, 14 days, 30 days, 3 months and 6 months post-procedure.

  5. Immune Response Analysis based on Information from Microbiome.

    Evaluation of changes in circulating microbiome post-histotripsy.

    Time frame: 36 hours, 14 days, 30 days, 3 months and 6 months post-procedure.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 24 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 23, 2026
StartActual
Nov 7, 2025
Primary completionEst.
Nov 7, 2027
CompletionEst.
May 7, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
National University Hospital is now Recruiting
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    National University Hospital is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07428356
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Nov 7, 2025
Primary completion
Nov 7, 2027 (estimated)
Completion
May 7, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS
Contact
brian.goh@singhealth.com.sg
+65 63265440
Sandra Hsing
Contact
sandra.hsing.san@nccs.com.sg
Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS
principal investigator · National Cancer Centre, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion